CLINICAL RESEARCH SHORT REPORT

MUSCLE&NERVE WILEY

Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice

Thomas Meyer MD [1,2] | Peggy Schumann MSc [2] | Patrick Weydt MD [3,4] | Susanne Petri MD [5] | Yasemin Koc RN [1] | Susanne Spittel PhD [2] | Sarah Bernsen MD [1,3] | René Günther MD [6,7] | Jochen H. Weishaupt MD [8] | Marie Dreger MD [1] | Felix Kolzarek MSc [2] | Dagmar Kettemann MD [1] | Jenny Norden MD [1] | Matthias Boentert MD [9] | Maximilian Vidovic MD [6] | Christian Meisel MD [10,11] | Christoph Münch MD [1,2] | André Maier MD [1] | Péter Körtvélyessy MD [1,12]

[1]Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany

[2]Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany

[3]Department for Neurodegenerative Disorders and Gerontopsychiatry, Bonn University, Bonn, Germany

[4]Deutsches Zentrum für Neurodegenerative Erkrankungen, Research Site Bonn, Bonn, Germany

[5]Department of Neurology, Hannover Medical School, Hannover, Germany

[6]Department of Neurology, Technische Universität Dresden, University Hospital Carl Gustav Carus, Dresden, Germany

[7]Deutsches Zentrum für Neurodegenerative Erkrankungen, Research Site Dresden, Dresden, Germany

[8]Neurology Department, Division for Neurodegenerative Diseases, University Medicine Mannheim, Heidelberg University, Mannheim Center for Translational Medicine, Mannheim, Germany

[9]Department of Neurology, Münster University Hospital, Münster, Germany

[10]Department of Immunology, Labor Berlin-Charité Vivantes GmbH, Berlin, Germany

[11]Charité-Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, Berlin, Germany

[12]Deutsches Zentrum für Neurodegenerative Erkrankungen, Research Site Magdeburg, Magdeburg, Germany

Correspondence
Thomas Meyer, Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany.
Email: thomas.meyer@charite.de

Abstract

Introduction/Aims: In amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (*SOD1*) gene mutations (SOD1-ALS), the antisense oligonucleotide tofersen had been investigated in a phase III study (VALOR) and subsequently introduced in an expanded access program. In this study we assess neurofilament light chain (NfL) before and during tofersen treatment.

Methods: In six SOD1-ALS patients treated with tofersen at three specialized ALS centers in Germany, NfL in cerebrospinal fluid (CSF-NfL) and/or serum (sNfL) were investigated using the ALS Functional Rating Scale Revised (ALSFRS-R) and ALS progression rate (ALS-PR), defined by monthly decline of ALSFRS-R.

Results: Three of the six SOD1-ALS patients reported a negative family history. Three patients harbored a homozygous c.272A > C, p.(Asp91Ala) mutation. These and two other patients showed slower progressing ALS (defined by ALS-PR <0.9), whereas one patient demonstrated rapidly progressing ALS (ALS-PR = 2.66). Mean treatment duration was 6.5 (range 5 to 8) months. In all patients, NfL decreased (mean CSF-NfL: −66%, range −52% to −86%; mean sNfL: −62%, range −36% to −84%). sNfL after 5 months of tofersen treatment was significantly reduced compared with the nearest pretreatment measurement ($P = .017$). ALS-PR decreased in two patients, whereas no changes in ALSFRS-R were observed in four participants who had very low ALS-PR or ALSFRS-R values before treatment.

Discussion: In this case series, the significant NfL decline after tofersen treatment confirmed its value as response biomarker in an expanded clinical spectrum of SOD1-ALS. Given the previously reported strong correlation between sNfL and ALS progression, the NfL treatment response supports the notion of tofersen having disease-modifying activity.

KEYWORDS
amyotrophic lateral sclerosis, neurofilament light chain, tofersen

1 | INTRODUCTION

In approximately 2% of people with amyotrophic lateral sclerosis (ALS), disease-causative, toxic gain-of-function mutations are found in the gene encoding superoxide dismutase 1 (*SOD1*).[1,2] Tofersen is an intrathecally administered antisense oligonucleotide degrading the SOD1 messenger RNA and reducing SOD1 protein levels.[3,4] Recently, tofersen has been investigated in a phase III trial (the VALOR study) that yielded a complex outcome, as the primary endpoint of Functional Rating Scale Revised (ALSFRS-R) did not reveal statistical significance, yet trends favored tofersen across secondary endpoints, including neurofilament light chain (NfL).[5–7] These early reductions in NfL, as observed in the VALOR trial, preceded the further slowing of ALSFRS-R decline during the open-label extension study.[5] The effect of tofersen on NfL was of particular relevance as NfL is an established prognostic biomarker of ALS for which a close correlation between NfL, ALS progression, and survival has been demonstrated.[8–12] Based on the positive signals from the phase III trial, an expanded access program (EAP) was started in which tofersen is provided to ALS patients with *SOD1* gene mutations (SOD1-ALS) outside of clinical trials. In Germany, the EAP was authorized in February 2022. Before the tofersen EAP, a large-scale, multicenter NfL study was initiated in which longitudinal clinical and serum NfL (sNfL) data are collected. This combination of the EAP with the ongoing NfL study provided a window of opportunity to analyze the clinical and biomarker course before and during tofersen treatment.

2 | METHODS

2.1 | Study design

This study involved the secondary use of existing data. The investigation was conducted in accordance with the STROBE criteria.[13]

2.2 | Study cohort

Data analysis was performed in patients fulfilling three main selection criteria: (1) diagnosis of ALS; (2) harboring an *SOD1* gene mutation; and (3) treatment with tofersen for at least 5 months.

2.3 | Setting

2.3.1 | Access to existing data

Patients at three multidisciplinary ALS centers in Germany (Berlin, Bonn, and Hannover) were identified. Data on clinical characteristics and NfL were obtained from the "NfL-ALS" study. *SOD1* mutation status was assessed in the "ID-ALS" study. Demographics, ALSFRS-R, and medication data, including tofersen treatment, were derived from the "APST registry study."

2.3.2 | Data collection

Demographic, clinical, and NfL data were captured up to 12 months before tofersen therapy and during the treatment. ALSFRS-R data were assessed by self-rating either on a printed form or using the ALS-App.[14] Data were collected between October 2021 and November 2022.

2.4 | NfL analysis

Serum NfL (sNfL) concentrations were analyzed in a core facility at the ALS center in Berlin. sNfL was measured using single-molecule analysis technology (SIMOA) and the commercially available NfL Advantage kit (Quanterix, Inc, Billerica, Massachusetts, USA). Cerebrospinal fluid (CSF) NfL concentrations (CSF-NfL) were measured at the Labor Berlin – Charité Vivantes GmbH using the NF-light enzyme-linked immunoassay (UmanDiagnostics, Umeå, Sweden).

2.5 | Protocol approvals and registrations

The study protocols were approved by the medical ethics committee of Charité–Universitätsmedizin Berlin, Germany. Written informed consent was obtained from all participants.

2.6 | Variables

2.6.1 | Clinical characteristics

Demographic data, *SOD1* mutation details, and clinical characteristics were collected.

2.6.2 | Functional deficit as measured by ALSFRS-R

The ALSFRS-R is a 12-item disease-specific instrument that measures bulbar, gross, and fine motor functions and respiratory symptoms.[15,16]

2.6.3 | ALS progression rate

ALS progression rate (ALS-PR) was calculated using the following formula: (48 − ALSFRS-R divided by disease duration [in months]).[17] Two classifications of ALS-PR were applied. In ALS-PR classification 1, patients with slower (<0.5 ALSFRS-R/month), intermediate (≥0.5 and ≤1.0 ALSFRS-R/month), and faster (>1.0 ALSFRS-R/month) progression were differentiated.[17] In ALS-PR classification 2, a distinction between faster progressing ALS (≥0.9 ALSFRS-R/month) and slower progressing ALS (<0.9 ALSFRS-R/month) was made.[5]

TABLE 1 Clinical and genetic characteristics

ID	Age (years)	M/F	Duration (months)	Family history	TIV	PEG	ALSFRS-R	ALS-PR	ALS-PR classification 1	ALS-PR classification 2	SOD1 mutation	Allele Genotype
#1	59	F	45	Negative	No	No	45	0.18	Slow	Slower progressing	C.272a > c, p.(asp91ala)	Homozygous
#2	59	M	33	Negative	No	No	46	0.06	Slow	Slower progressing	C.272a > c, p.(asp91ala)	Homozygous
#3	49	F	22	Negative	No	No	42	0.27	Slow	Slower progressing	C.272a > c, p.(asp91ala)	Homozygous
#4	54	M	105	Positive	No	No	43	0.05	Slow	Slower progressing	C.346c > g/p.(arg116gly)	Heterozygous
#5	60	F	16	Positive	No	No	35	0.80	Intermediate	Slower progressing	C.346c > g, p.(arg116gly)	Heterozygous
#6	39	F	18	Positive	Yes	Yes	1	2.66	Fast	Faster progressing	C.396_399dup, p.(glu134*)	Heterozygous

Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale Revised; ALS-PR, ALS progression rate before tofersen treatment; duration, disease duration; F, female; M, male; PEG, percutaneous endoscopic gastrostomy; TIV, tracheostomy invasive ventilation.

TABLE 2 NfL and clinical course in SOD1-ALS patients before and during tofersen treatment

Patient 1 (duration 42 months)

Disease course (months) / Outcome	sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC
−10	39.47				142
−7					127
−2	28.53		45	0.07	
−1	59.68				157
0	61.59	2607	45	0.07	125
0.5	58.80	2557	45		120
1	63.26	3094	43	0.12	135
2	23.32				117
3	41.61	1484	42	0.13	109
4	20.20	1748	43	0.11	132
5	32.98	1121			112
6	18.15	776			112
7	18.35	1235	42	0.12	122
8			43	0.10	
Change	−70%	−53%	−2	0.05	−3

Patient 2 (duration 32 months)

Outcome	sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC
−2	53.90		44	0.13	104
−1			46	0.06	
0	63.26	2965	46	0.06	85
0.5	37.20	2968	45	0.09	89
1	107.88	1596	45	0.09	113
2	83.70	1977	45	0.09	108
3	37.31	2187	40	0.11	131
4	45.55	1527	44	0.11	114
5	36.25	1298	44	0.11	111
6	33.54	1370	44	0.11	112
7		958	44	0.10	107
Change	−47%	−68%	−2	0.04	22

Patient 3 (duration 22 months)

Outcome	sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC
−2	83.77		42	0.30	97
−1			43	0.24	
0	107.01	2182	42	0.27	95
0.5	108.07	2864	41	0.12	100
1	132.48	1400	42	0.26	96
2	66.03	1415	42	0.25	89
3	24.14	1282	43	0.20	102
4	42.09	1349	43	0.19	100
5	28.06	934	43	0.19	100
6	17.57	1041	43	0.18	97
7		577	43	0.17	103
Change	−84%	−52%	1	−0.10	8

Patient 4 (duration 108 months)

Disease course (months) / Outcome	sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC
−3	87.20		43	0.05	120
0	177.41	17490	45	0.03	96
0.5	177.39	15607			116
1	92.35	13663			103
2	50.42	4817	45	0.03	96
3	51.15	4187	42	0.05	96
4	31.39	2493	45	0.03	89
5	30.87	3566	45	0.03	104

Patient 5 (duration 16 months)

Outcome	sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC
−6	90.3		41	1.0	
−5			39	0.9	
−3			40	0.6	
−2			36	0.9	
0	62.3		35	0.8	
0.5			32	0.9	
1			31	0.9	
2			33	0.8	
3			32	0.8	
5	29.3		32	0.8	

Patient 6 (duration 18 months)

Outcome	sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC
−6	271	6765	21	7.06	
0	390	6741	1	3.71	
0.5	352	6717	1	3.71	
1	315	5802	1	3.44	
2	284	4410	1	3.21	
3	252	3018	1	3.00	
4	248	3117	1	2.82	
5	249	2070	1	2.66	

TABLE 2 (Continued)

Parameters	Outcome	Patient 4 (duration 108 months)					Patient 5 (duration 16 months)					Patient 6 (duration 18 months)				
		sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC	sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC	sNfL	NfL-CSF	ALS-FRS-R	ALS-PR	SVC
	6								32	0.7						
	7								33	0.7						
Change[a]		−83%	−86%	0	0	8	−53%		−2	−0.1		−36%	−69%	0	−1.05	

Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale Revised; ALS-PR, ALS progression rate; duration, disease duration in months; NfL-CSF, neurofilament light chain in CSF (pg/mL); sNfL, neurofilament light chain in serum (pg/mL); SVC, slow vital capacity as measured in percent of the predicted value (corrected for height, age, sex, and weight).

Note: Duration indicates duration of disease. Gray-shaded area: values before treatment; blue-shaded area: values during treatment; unshaded area: no measurements available.

[a]Change from initiation of tofersen treatment to the last measured value.

2.6.4 | sNfL and CSF-NfL

sNfL and CSF-NfL concentrations were analyzed as described and referred to the time of sampling.

2.6.5 | Tofersen treatment

Treatment with tofersen was assessed as the number of months receiving tofersen.

2.7 | Statistical methods

Descriptive statistics were used (frequency in percent, mean, median, and ranges) and statistical analyses were performed by StatPlus version 7.7.11 (AnalystSoft, Brandon, Florida, USA) and GraphPad Prism version 9.0.0 (GraphPad, San Diego, California, USA). Mann-Whitney U test and repeated-measures analysis of variance with Greisser-Greenhouse correction were applied. $P \leq .05$ was considered significant.

3 | RESULTS

3.1 | Patient cohort and clinical characteristics

Six SOD1-ALS patients with three unique *SOD1* mutations were investigated. Three of these six patients reported a negative family history. Clinical characteristics are summarized in Table 1 and Data S1. The mean tofersen treatment duration was 6.5 (range 5 to 8) months.

3.2 | ALSFRS-R before and during tofersen treatment

Five patients showed high functional status at the time of treatment initiation, whereas one patient showed profound loss of motor function. Results are summarized in Table 2.

3.3 | ALS-PR before and during tofersen treatment

ALS-PR before tofersen treatment was slow in four patients (range .05 to .27), intermediate in one patient (0.8), and fast in another case (2.66) (Table 1). Other results are summarized in Table 2.

3.4 | sNfL and CSF-NfL before and during tofersen treatment

In all patients, CSF-NfL (ΔCSF-NfL: −66% [range −52 to −86], $P = .028$) and sNfL (ΔsNfL: −62% [range −36 to −84]; $P = .049$) significantly

FIGURE 1 Serum neurofilament light chain (sNfL) before and during treatment with tofersen. A, Individual slopes of sNfL concentration during ALS disease course (patients 1 to 5). B, Individual slope of sNfL concentration (patient 6). C, sNfL pretreatment (M0; except 5 M-2) compared with on treatment (M5). M0, month of initiation of tofersen treatment; M-2, 2 months before tofersen treatment; M5, 5 months of tofersen treatment. *$P \leq .05$ considered significant.

decreased during tofersen treatment compared with baseline. Repeated-measures analysis of variance also showed significant results (sNfL: $P = .047$). Results are summarized in Table 2 and Figure 1.

4 | DISCUSSION

In this study we have undertaken an exploratory analysis of NfL in six SOD1-ALS patients treated with tofersen as part of an EAP. In fact, all patients showed a significant NfL decrease in response to tofersen therapy. Thus, the principle finding of NfL responsiveness was reproduced, as previously demonstrated in the VALOR and open-label extension study.[5]

Furthermore, our study has expanded the treatment experience with tofersen as five of the six EAP patients showed clinical characteristics that were not included or were less frequent in the VALOR study. One patient underwent invasive ventilation and had near-total loss of motor function (ALSFRS-R = 1), a functional deficit not reported in VALOR (minimum ALSFRS-R score = 15).[5] Three patients harbored a homozygous Asp91Ala mutation, which was rarely included in the VALOR study (n = 2, 1.9%).[5] Two patients showed a very slow progression (ALS-PR before treatment of 0.05 and 0.06, respectively; Table 1), which was well below the mean ALSFRS-R slope of the VALOR slower progression subgroup (−0.30 ± 0.20).[5] Despite the different clinical and genetic characteristics of the treated patients, the decrease in NfL was a common feature of tofersen therapy. Also, the extent of NfL reduction was comparable to that seen in the VALOR data.[5] This finding underscores the feasibility of NfL as a therapeutic biomarker in an expanded clinical spectrum of SOD1-ALS, including very slow progression or severe motor deficits.

Four of the six patients were treated for at least 7 months and thus correspond to the placebo-controlled phase of the VALOR trial (28 weeks).[5] Nevertheless, our findings must be considered in the context of some limitations. With six patients and the short treatment time, the scope of our study was limited. In particular, in patients with slow ALS progression, a longer observation time is essential to establish a correlation between the clinical and biomarker treatment response. Given the pathophysiological role of NfL as an indicator of neuroaxonal damage and the strong correlation between NfL and ALS progression, the prognostic significance of NfL reduction can be assumed but requires confirmation by further research. More specifically, a continued investigation of our cohort as well as the inclusion of additional patients will clarify the latency and effect size in which NfL response converges with clinical outcome including ALSFRS-R.

The ALSFRS-R was the primary endpoint in the VALOR trial and was also of interest in this case series. Two patients (patients 3 and 5) showed a reduction of ALS-PR. Although any individual case data must be treated with caution, these EAP participants showed that a reduction in NfL was associated with a stabilization of the clinical course. Three of the six patients showed such a slow progression rate that, given the short duration of therapy, no change in ALSFRS-R could be expected. Furthermore, in one patient (patient 6), the ALSFRS-R (total score = 1) became uninformative due to the floor effect of the instrument.[18] With a longer duration of treatment with tofersen, it will be of major interest whether patients with large deficits also show a stabilization of the disease or even a return of certain motor functions. In patients with severe deficits or slow progression, the assessment of patient-reported outcomes (PROs) will be of particular importance, which allows a systemic detection of apparently minor changes that are not reflected in the

ALSFRS-R but may have a high functional meaning at the individual level. Thus, systematic analysis of PROs in patients with spinal muscular atrophy and nusinersen treatment has shown a response to therapy in addition to and beyond clinical functional scores.[19]

Overall, the NfL data correspond with the VALOR results and underscore the role of NfL as an early treatment response marker in ALS. Furthermore, the data presented support the disease-modifying activity of tofersen in SOD1-ALS. The expansion of the observation in terms of treated *SOD1* mutations, treatment duration, the number of included patients, and by that means of ALSFRS-R endpoint data, as well as the exploration of PROs, will provide additional information on the efficacy of tofersen in SOD1-ALS.

CONFLICT OF INTEREST STATEMENT
T.M. is on the advisory board of Biogen and has received consulting fees from Biogen. P.K. received consulting fees from Biogen. R.G. has received grants, personal fees, nonfinancial support, and research support from Biogen and serves on the advisory board of Biogen, outside of the submitted work. S.P. has participated on advisory boards of Biogen and has received consulting fees from Biogen. T.M. and C.M. are founders and shareholders of the Ambulanzpartner Soziotechnologie APST GmbH, which makes the internet platform Ambulanzpartner and the mobile application ALS-App. APST received a research grant from Biogen.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICAL PUBLICATION STATEMENT
The authors confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

ORCID
Thomas Meyer 🔟 https://orcid.org/0000-0002-2736-7350
Matthias Boentert 🔟 https://orcid.org/0000-0001-6133-1397
André Maier 🔟 https://orcid.org/0000-0003-2473-4116

REFERENCES
1. Rosen D, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature.* 1993;362:59-62.
2. Müller K, Brenner D, Weydt P, et al. Comprehensive analysis of the mutation spectrum in 301 German ALS families. *J Neurol Neurosurg Psychiatry.* 2018;89:817-827.
3. Bunton-Stasyshyn RK, Saccon RA, Fratta P, Fisher EM. SOD1 function and its implications for amyotrophic lateral sclerosis pathology: new and renascent themes. *Neuroscientist.* 2015;21:519-529.
4. McCampbell A, Cole T, Wegener AJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. *J Clin Invest.* 2018;128:3558-3567.
5. Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. *N Engl J Med.* 2022;387:1099-1110.
6. Miller TM, Cudkowicz ME, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. *N Engl J Med.* 2020;383:109-119.
7. Hardiman O, van den Berg LH. The beginning of genomic therapies for ALS. *N Engl J Med.* 2020;383:180-181.
8. Feneberg E, Oeckl P, Steinacker P, et al. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. *Neurology.* 2018;90:e22-e30.
9. Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. *J Neurol Neurosurg Psychiatry.* 2016;87:12-20.
10. Thouvenot E, Demattei C, Lehmann S, et al. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. *Eur J Neurol.* 2020;27:251-257.
11. Benatar M, Zhang L, Wang L, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. *Neurology.* 2020;95:e59-e69.
12. Dreger M, Steinbach R, Gaur N, et al. Cerebrospinal fluid neurofilament light chain (NfL) predicts disease aggressiveness in amyotrophic lateral sclerosis: an application of the D50 disease progression model. *Front Neurosci.* 2021;15:651651.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet.* 2007;370:1453-1457.
14. Meyer T, Spittel S, Grehl T, et al. Remote digital assessment of amyotrophic lateral sclerosis functional rating scale---a multicenter observational study. *Amyotroph Lateral Scler Frontotemporal Degener.* 2022;1:1-10. doi:10.1080/21678421.2022.2104649
15. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (phase III). *J Neurol Sci.* 1999;169:13-21.
16. Maier A, Boentert M, Reilich P, et al. ALSFRS-R-SE: an adapted, annotated, and self-explanatory version of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale. *Neurol Res Pract.* 2022;4:60.
17. Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. *Neurology.* 2006;66:265-267.
18. Wicks P, Massagli MP, Wolf C, Heywood J. Measuring function in advanced ALS: validation of ALSFRS-EX extension items. *Eur J Neurol.* 2009;16:353-359.
19. Meyer T, Maier A, Uzelac Z, et al. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. *Eur J Neurol.* 2021;28:2582-2595.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.